Last reviewed · How we verify

Betamethasone plus calcipotriol — Competitive Intelligence Brief

Betamethasone plus calcipotriol (Betamethasone plus calcipotriol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glucocorticoid receptor agonist and retinoid X receptor agonist. Area: Dermatology.

phase 2 Glucocorticoid receptor agonist and retinoid X receptor agonist Glucocorticoid receptor and retinoid X receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Betamethasone plus calcipotriol (Betamethasone plus calcipotriol) — LEO Pharma. Betamethasone is a glucocorticoid receptor agonist, while calcipotriol is a vitamin D3 analog that acts as a retinoid X receptor agonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Betamethasone plus calcipotriol TARGET Betamethasone plus calcipotriol LEO Pharma phase 2 Glucocorticoid receptor agonist and retinoid X receptor agonist Glucocorticoid receptor and retinoid X receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glucocorticoid receptor agonist and retinoid X receptor agonist class)

  1. LEO Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Betamethasone plus calcipotriol — Competitive Intelligence Brief. https://druglandscape.com/ci/betamethasone-plus-calcipotriol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: